MOLECULAR MECHANISMS AND THERAPEUTIC FRONTIERS IN TYPE 2 DIABETES MELLITUS: A COMPREHENSIVE ANALYTICAL REVIEW
Abstract
Type 2 Diabetes Mellitus (T2DM) represents a multifaceted metabolic crisis characterized by a progressive decline in glucose homeostasis. This review provides an extensive examination of the disease, moving from its intricate molecular pathogenesis to the most recent shifts in clinical management. We explore the critical synergy between lifestyle intervention and a new generation of "organ-protective" pharmacological agents, such as SGLT2 inhibitors and GLP-1 receptor agonists. Furthermore, the review addresses the underlying causes of disease heterogeneity, the "Ominous Octet" of organ dysfunction, and the barriers to successful long-term glycemic control. By integrating genetic susceptibility and molecular triggers, this work emphasizes the necessity of a personalized, patient- centered approach in modern diabetology.
References
1. Davies M.J. et al. Management of hyperglycaemia in type 2 diabetes. Diabetologia, 2022.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care, 2024.
3. International Diabetes Federation. IDF Diabetes Atlas, 10th edition, 2021.
4. Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med, 2015.Marso S.P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2016.
5. DeFronzo R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes, 2009.
6. Kahn S.E. et al. Pathophysiology and treatment of type 2 diabetes. Lancet, 2014.
7. Neal B. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med, 2017.
8. Saeedi P. et al. Global diabetes prevalence. Diabetes Res Clin Pract, 2019.
9. Sun H. et al. IDF Diabetes Atlas estimates. Diabetes Research, 2022.
10. McGuire D.K. et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes. JAMA Cardiol, 2021.
11. Buse J.B. et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes. Diabetes Care, 2020.
12. Knowler W.C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002.
13. Gerstein H.C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet, 2019.
14. Wiviott S.D. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2019.
15. Inzucchi S.E. et al. Management of Hyperglycemia in Type 2 Diabetes. Diabetes Care, 2015.
16. Heerspink H.J.L. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2020.
17. Stratton I.M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ, 2000.
18. Perkovic V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 2019.
19. Kristensen S.L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists. Lancet Diabetes Endocrinol, 2019.
